文献速递类风湿关节炎其他结缔组织病

阿巴西普治疗类风湿关节炎相关间质性肺病的全国多中心研究

Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该观察性多中心研究纳入263例接受阿巴西普治疗的RA-ILD患者,中位随访12个月。结果显示多数患者呼吸困难、肺功能及高分辨率CT未恶化,DAS28ESR显著改善,糖皮质激素用量减少,提示阿巴西普可能有效且安全。

要点

  • 阿巴西普治疗期间91.9%患者呼吸困难未恶化,87.7%患者FVC未恶化。
  • DAS28ESR从4.5降至3.1,糖皮质激素中位剂量从7.5 mg/day降至5 mg/day。
  • 23.6%患者因不良事件、关节疗效不足或ILD恶化等原因停药。

核心结论

  • 阿巴西普可能对RA-ILD患者有效且安全。

研究设计与样本

  • 观察性多中心研究,纳入263例接受至少一剂阿巴西普治疗的RA-ILD患者,ILD经高分辨率CT诊断。

主要发现

  • 中位随访12个月,91.9%患者MMRC呼吸困难评分未恶化,87.7%患者FVC未恶化,90.6%患者DLCO未恶化,76.6%患者胸部HRCT未恶化。
  • DAS28ESR从基线4.5(1.5)显著改善至随访结束时3.1(1.3),P < 0.001。
  • 糖皮质激素用量中位值从7.5(5-10)mg/day显著降至5(2.5-7.5)mg/day,P < 0.001。
  • 62例(23.6%)患者停用阿巴西普,原因包括不良事件(n = 30)、关节疗效不足(n = 27)、ILD恶化(n = 3)及其他原因(n = 2)。

关键数值与推荐

  • 基线时ILD中位病程1(0.25-3.44)年,40.3%患者有中度或重度呼吸困难(MMRC 2、3或4级)。
  • 基线FVC占预计值平均85.9%(21.8)%,DLCO占预计值65.7%(18.3)%,DAS28ESR 4.5(1.5)。
  • ILD类型:UIP占40.3%,NSIP占31.9%,其他占27.8%。
  • 阿巴西普给药方式:静脉25.5%,皮下74.5%,均为标准剂量。

临床怎么用

  • 对于RA-ILD患者,阿巴西普可考虑作为改善关节症状并可能稳定ILD的治疗选择。
  • 治疗期间需监测ILD恶化及不良事件,研究中有3例因ILD恶化停药。

局限性

  • 本研究为观察性研究,缺乏对照组,无法确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy of abatacept (ABA) in RA patients with interstitial lung disease (ILD) (RA-ILD). METHODS: This was an observational, multicentre study of RA-ILD patients treated with at least one dose of ABA. ILD was diagnosed by high-resolution CT (HRCT). We analysed the following variables at baseline (ABA initiation), 12 months and at the end of the follow-up: Modified Medical Research Council (MMRC) scale (1-point change), forced vital capacity (FVC) or diffusion lung capacity for carbon monoxide (DLCO) (improvement or worsening ≥10%), HRCT, DAS on 28 joints evaluated using the ESR (DAS28ESR) and CS-sparing effect. RESULTS: We studied 263 RA-ILD patients [150 women/113 men; mean (s.d.) age 64.6 (10) years]. At baseline, they had a median duration of ILD of 1 (interquartile range 0.25-3.44) years, moderate or severe degree of dyspnoea (MMRC grade 2, 3 or 4) (40.3%), FVC (% of the predicted) mean (s.d.) 85.9 (21.8)%, DLCO (% of the predicted) 65.7 (18.3) and DAS28ESR 4.5 (1.5). The ILD patterns were: usual interstitial pneumonia (UIP) (40.3%), non-specific interstitial pneumonia (NSIP) (31.9%) and others (27.8%). ABA was prescribed at standard dose, i.v. (25.5%) or s.c. (74.5%). After a median follow-up of 12 (6-36) months the following variables did not show worsening: dyspnoea (MMRC) (91.9%); FVC (87.7%); DLCO (90.6%); and chest HRCT (76.6%). A significant improvement of DAS28ESR from 4.5 (1.5) to 3.1 (1.3) at the end of follow-up (P < 0.001) and a CS-sparing effect from a median 7.5 (5-10) to 5 (2.5-7.5) mg/day at the end of follow-up (P < 0.001) was also observed. ABA was withdrawn in 62 (23.6%) patients due to adverse events (n = 30), articular inefficacy (n = 27), ILD worsening (n = 3) and other causes (n = 2). CONCLUSION: ABA may be an effective and safe treatment for patients with RA-ILD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fernández-Díaz C, Castañeda S, Melero-González RB, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology (Oxford). 2020. PMID: 33068439. doi:10.1093/rheumatology/keaa621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。